TWI777606B - Traditional chinese medicine formula flora capsule, preparation method and use thereof in preparing medicine for treating type 2 diabetes - Google Patents

Traditional chinese medicine formula flora capsule, preparation method and use thereof in preparing medicine for treating type 2 diabetes Download PDF

Info

Publication number
TWI777606B
TWI777606B TW110120881A TW110120881A TWI777606B TW I777606 B TWI777606 B TW I777606B TW 110120881 A TW110120881 A TW 110120881A TW 110120881 A TW110120881 A TW 110120881A TW I777606 B TWI777606 B TW I777606B
Authority
TW
Taiwan
Prior art keywords
chinese medicine
traditional chinese
medicine formula
flora
capsule
Prior art date
Application number
TW110120881A
Other languages
Chinese (zh)
Other versions
TW202135848A (en
Inventor
徐福寧
徐傳友
黃紅麗
陳慶林
盛健
徐奚如
Original Assignee
大陸商南京法邁特科技發展有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商南京法邁特科技發展有限公司 filed Critical 大陸商南京法邁特科技發展有限公司
Publication of TW202135848A publication Critical patent/TW202135848A/en
Application granted granted Critical
Publication of TWI777606B publication Critical patent/TWI777606B/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/25Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258Panax (ginseng)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/81Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815Lycium (desert-thorn)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/896Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8969Polygonatum (Solomon's seal)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/906Zingiberaceae (Ginger family)
    • A61K36/9066Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention belongs to the field of medicines, and particularly relates to a traditional Chinese medicine formula flora capsule which is prepared by matching freeze-dried powder separated from fecal floral and traditional Chinese medicine extraction powder obtained by crushing traditional Chinese medicine extraction effective ingredients. The invention combines the traditional Chinese medicine extraction method and deeply integrates it with the fecal floral separation process to prepare the traditional Chinese medicine formula flora capsule, which greatly improves the treatment effect while changing the administration method, and realizes an efficient and comfortable treatment way.

Description

中藥配方菌群膠囊及製備方法和在製備治療2型糖尿病的藥物中的應用Traditional Chinese medicine formula bacteria capsule, preparation method and application in preparation of medicine for treating type 2 diabetes

本發明屬藥物技術領域,具體涉及糞菌移植技術領域,更具體涉及一種中藥配方糞菌膠囊,其製備方法,以及在製備治療2型糖尿病的藥物中的應用。 The invention belongs to the technical field of medicine, in particular to the technical field of fecal bacteria transplantation, and more particularly to a traditional Chinese medicine formula fecal bacteria capsule, a preparation method thereof, and an application in the preparation of a medicine for treating type 2 diabetes.

腸道菌群結構和功能改變可引起肥胖、2型糖尿病等一系列代謝性疾病,近年來的研究提示,糞菌移植治療可改善2型糖尿病的血糖控制水平,改善代謝,提高胰島素敏感性。 Changes in the structure and function of intestinal flora can lead to a series of metabolic diseases such as obesity and type 2 diabetes. Recent studies have suggested that fecal microbiota transplantation can improve the level of blood sugar control in type 2 diabetes, improve metabolism, and improve insulin sensitivity.

“糞菌移植”(Fecal microbiota transplantation,FMT),其定義是,將健康者糞便中的功能菌群通過鼻胃管或十二指腸管、胃鏡或結腸鏡、直腸導管灌腸等方式移植到患者胃腸道內,重建腸道菌群的平衡,修復腸道粘膜的屏障,實現對特定腸道內及腸道外疾病的治療。 "Fecal microbiota transplantation" (FMT), which is defined as the transplantation of functional flora in the stool of a healthy person into the gastrointestinal tract of a patient through nasogastric or duodenal tube, gastroscope or colonoscopy, rectal catheter enema, etc. , Rebuild the balance of intestinal flora, repair the barrier of intestinal mucosa, and realize the treatment of specific intestinal and extra-intestinal diseases.

然而,上述給藥方式雖可達到腸菌移植治療目的,但其需在置管狀態或內鏡下將菌液輸注到患者腸道進行治療,患者生理及心理接受度有限,從而限制了這一治療技術在臨床的推廣應用。如田宏亮等(菌群膠囊治療慢性傳輸型便秘15例臨床療效分析,中國實用外科雜志2016年4月第36卷第4期)報道采用菌群膠囊治療慢性傳輸型便秘15例臨床療效分析,但其研究結果是初步嘗 試,也未納入對照組,如何克服糞菌移植的缺點還是不够。尤其是該文章中的菌群膠囊內容物為單一的菌液,而且需要添加常規輔料會减少菌液含量,因此有必要進行進一步的研發,將糞菌移植更好地應用于疾病的治療。 However, although the above-mentioned administration method can achieve the purpose of intestinal bacteria transplantation, it needs to infuse the bacterial solution into the patient's intestine for treatment under the intubation state or under the endoscope, and the patient's physical and psychological acceptance is limited, which limits this The promotion and application of treatment technology in clinical practice. For example, Tian Hongliang et al. (Analysis of clinical efficacy of microflora capsules in the treatment of 15 cases of chronic transit constipation, Chinese Journal of Practical Surgery, Vol. The results of the study are preliminary It was not included in the control group, so how to overcome the shortcomings of fecal microbiota transplantation is still not enough. In particular, the content of the microflora capsule in this article is a single bacterial liquid, and the addition of conventional excipients will reduce the bacterial liquid content. Therefore, it is necessary to carry out further research and development to better apply fecal bacteria transplantation to the treatment of diseases.

針對上述問題,本發明人將傳統的給藥方式,通過新鮮的菌液提取出來,製備成凍乾粉,但單純的菌液凍乾粉有時需配套使用中藥以提升治療質量,鑒于此本發明人結合中藥萃取方法,將兩種工藝進行深度融合,製成中藥配方菌群膠囊,在改變給藥方法的同時極大地提高了治療效果,實現了高效、舒適的治療途徑。 In view of the above-mentioned problems, the present inventor extracted the traditional method of administration from fresh bacterial liquid and prepared it into freeze-dried powder, but the simple bacterial liquid freeze-dried powder sometimes needs to be matched with traditional Chinese medicine to improve the quality of treatment. In view of this The inventor combined the traditional Chinese medicine extraction method and deeply integrated the two processes to make the traditional Chinese medicine formula bacteria group capsule, which greatly improved the therapeutic effect while changing the administration method, and realized an efficient and comfortable treatment route.

本發明提供的技術方案是:一方面,本發明提供一種中藥配方菌群膠囊,其特徵在于,其由糞菌分離後的凍乾粉和中藥萃取有效成分粉碎得到中藥萃取粉末配合製備得到。 The technical solutions provided by the present invention are as follows: On the one hand, the present invention provides a traditional Chinese medicine formula flora capsule, which is characterized in that it is prepared by cooperating with the freeze-dried powder after the separation of fecal bacteria and the traditional Chinese medicine extraction powder obtained by pulverizing the effective components of the traditional Chinese medicine extraction.

在一個具體實施方式中,所述糞菌分離方法是腔道內容物中微生物分離裝置進行分離,更具體是采用201410606325.4專利中描述的裝置進行分離。 In a specific embodiment, the method for separating fecal bacteria is to separate the microorganisms in the contents of the cavity, and more specifically, to use the device described in the 201410606325.4 patent for separation.

更具體地,所述糞菌分離後的凍乾粉的製備方法包括如下步驟:(1)用無菌采樣瓶收集健康供者的糞便樣本,密封送至無菌操作室,與無菌一次性使用耗材中的過濾瓶、AB瓶、除臭瓶、緩衝瓶、菌液瓶配合串聯放置在智能糞菌分離系統中進行菌群收集;(2)通過加液驅動裝置將生理鹽水加注到采樣瓶中對糞便樣本進行浸泡;(3)打開氣泵二將采樣瓶中的混合菌液依次通過不同過濾值的過濾網彙集到緩衝瓶中,再通過菌液驅動裝置將緩衝瓶中的菌液灌注到菌液瓶中 後進行離心,離心完成去掉上清液,保留沉澱,此沉澱即為分離純化後的菌液沉澱;(4)向每個離心管中加入甘油,用振蕩器混勻,將其預凍,預凍完成後迅速將預凍後樣品進行冷凍乾燥,將凍乾後的菌液脫水後得到凍乾粉。 More specifically, the preparation method of the lyophilized powder after the separation of the fecal bacteria comprises the following steps: (1) collecting fecal samples of healthy donors with a sterile sampling bottle, sealing and sending them to a sterile operating room, and mixing them with sterile disposable consumables. The filter bottle, AB bottle, deodorization bottle, buffer bottle, and bacterial liquid bottle are placed in series in the intelligent fecal bacteria separation system to collect bacteria; Soak the stool samples; (3) Turn on the air pump 2 to collect the mixed bacterial liquid in the sampling bottle into the buffer bottle through filters with different filter values in turn, and then perfuse the bacterial liquid in the buffer bottle into the bacterial liquid through the bacterial liquid driving device. bottle After centrifugation, the supernatant was removed after the centrifugation, and the precipitate was retained. This precipitate was the bacterial liquid precipitate after separation and purification; (4) Add glycerol to each centrifuge tube, mix with a shaker, pre-freeze it, and pre-freeze it. After the freezing is completed, the pre-frozen samples are quickly freeze-dried, and the freeze-dried bacterial liquid is dehydrated to obtain freeze-dried powder.

進一步優選地,所述采樣瓶中設有攪拌杆,步驟(2)中,采樣瓶中的攪拌杆對糞便樣品進行攪拌使其充分均質。 Further preferably, the sampling bottle is provided with a stirring rod, and in step (2), the stirring rod in the sampling bottle stirs the stool sample to make it fully homogenized.

在優選實施方式中,所述的菌群凍乾粉和所述的中藥萃取粉末的體積比為0.5-2:1,更優選為1:1。具體是將兩者混合後微型攪拌機攪拌混勻制得,幷進一步用耐酸羥丙甲纖維素膠囊灌裝。 In a preferred embodiment, the volume ratio of the bacterial flora freeze-dried powder and the traditional Chinese medicine extraction powder is 0.5-2:1, more preferably 1:1. Specifically, it is prepared by mixing the two with a micro-mixer, and then further filling with acid-resistant hypromellose capsules.

在一個更優選的實施方式中,所述的中藥萃取粉末是從西洋參、黃精、神曲、地骨皮、莪術的中藥配方萃取的有效成分,進行粉碎得到。更優選地,所述的中藥配方中西洋參、黃精、神曲、地骨皮、莪術的重量比為8-12:12-18:12-18:8-12:8-12,優選為10:15:15:10:10。 In a more preferred embodiment, the Chinese herbal extract powder is obtained by pulverizing the active ingredients extracted from the Chinese herbal formulas of American ginseng, Polygonatum chinensis, Divine Comedy, Digupi and Curcuma Radix. More preferably, the weight ratio of American ginseng, Polygonatum chinensis, Divine Comedy, Digupi and Curcuma in the Chinese medicine formula is 8-12:12-18:12-18:8-12:8-12, preferably 10: 15:15:10:10.

其中藥有效成分的提取可按常規方法進行,在一個具體實施方式中,所述中藥萃取粉末製備方法如下,(1)按比例取藥材切碎或粉碎,置煎煮容器中;(2)加水浸浸泡;(3)加熱至沸,浸出,分離煎出液,藥渣依法煎出2-3次,收集煎出液;(4)將煎出液進行醇提取,優選為乙醇提取;(5)醇提取的濾液烘乾後再用超微粉碎機對其進行粉碎加工,優選為低于10μm的超細粉。 The extraction of the active ingredients of traditional Chinese medicine can be carried out by conventional methods. In a specific embodiment, the preparation method of the traditional Chinese medicine extraction powder is as follows: (1) chop or pulverize the medicinal materials in proportion, and place them in a decoction container; (2) add water (3) heating to boiling, leaching, separating the decocted liquid, decocting the dregs for 2-3 times according to the law, and collecting the decocted liquid; (4) carrying out alcohol extraction with the decoction liquid, preferably ethanol extraction; (5) ) The filtrate of alcohol extraction is dried and then pulverized with an ultrafine pulverizer, preferably an ultrafine powder less than 10 μm .

本發明還提供所述的中藥配方菌群膠囊在製備治療2型糖尿病的藥物中的應用。 The present invention also provides the application of the traditional Chinese medicine formula microflora capsule in preparing a medicine for treating type 2 diabetes.

本發明還提供上述的中藥配方菌群膠囊的製備方法,其包括將糞菌分離後的凍乾粉與中藥萃取有效成分粉碎混合均勻的步驟,其中將兩者混合後微型攪拌機攪拌混勻制得,幷進一步用耐酸羥丙甲纖維素膠囊灌裝。 The present invention also provides the preparation method of the above-mentioned traditional Chinese medicine formula flora capsule, which comprises the steps of pulverizing and mixing the freeze-dried powder after separation of the fecal bacteria and the active ingredients extracted from the traditional Chinese medicine, wherein after mixing the two, a micro-mixer stirs and mixes to obtain a , and further filled with acid-resistant hypromellose capsules.

本發明進一步提供一種治療2型糖尿病的藥物的中藥組合物,所述組合物包括西洋參、黃精、神曲、地骨皮、莪術,其中它們的重量比為為8-12:12-18:12-18:8-12:8-12,優選為10:15:15:10:10。 The present invention further provides a traditional Chinese medicine composition of a medicine for treating type 2 diabetes, the composition comprises American ginseng, Polygonatum chinensis, Divine Comedy, Digupi, Curcuma, wherein the weight ratio of them is 8-12:12-18:12 -18:8-12:8-12, preferably 10:15:15:10:10.

其中對于本發明治療機理,本發明人是根據糖尿病臨床特點,其歸屬于中醫學“消渴”範疇。傳統中醫認為消渴的主要病機是“陰虛為主,燥熱為標”。中醫認為,消渴之“熱”,究其本源有“燥熱”、“濕熱”、“瘀熱”之別,三熱之中,以瘀熱致病最難除,變證最多,為消渴日久變生多種頑疾的主要病理因素。又氣能生津,滋陰潤燥的同時給予益氣藥,則可收到更好的補陰作用。針對糖尿病陰虛為本、瘀熱夾雜的病機特點,擬定益氣養陰,清熱活血的治法,本發明人從西洋參、黃精、神曲、地骨皮、莪術中萃取有效成分,將將萃取的中藥有效成分粉碎後與糞菌凍乾粉精妙結合後製成膠囊,進行了其對2型糖尿病的療效探索。本發明中,西洋參為君藥,益氣生津,滋陰潤燥清熱,治療糖尿病陰虛之本。黃精、地骨皮、莪術為臣藥,其中黃精性平,補氣養陰,潤肺益腎,助西洋參益氣生津;地骨皮清熱凉血,莪術行氣破瘀,兼能健脾,地骨皮、莪術同用,清熱凉血化瘀,治療瘀熱之症候。神曲為佐,健脾和胃,消食化積,有祛胃腸積熱,促進氣機條暢作用。本方藥精而力專,一藥多效,配伍嚴謹,切合病機。同時,本方藥物都經現代藥理學驗證具有調節血糖、降脂或改善血流動力學的作用,神曲亦能改善腸道菌群失調,中西貫通,說服力强。 For the treatment mechanism of the present invention, the inventors based on the clinical characteristics of diabetes, which belongs to the category of "diabetes" in traditional Chinese medicine. Traditional Chinese medicine believes that the main pathogenesis of diabetes is "Yin deficiency is the main factor, and dryness and heat are the standard". Chinese medicine believes that the origin of the "heat" of diabetes is divided into "dry heat", "damp heat" and "stasis heat". The main pathological factors of a variety of stubborn diseases over time. And qi can generate body fluid, nourish yin and moisten dryness while giving qi medicine, you can receive better yin nourishing effect. Aiming at the pathogenesis characteristics of diabetes based on yin deficiency and mixed with blood stasis and heat, a treatment method for nourishing qi and nourishing yin, clearing heat and activating blood is formulated. The extracted active ingredients of traditional Chinese medicine were crushed and combined with fecal bacteria freeze-dried powder to make capsules, and their curative effects on type 2 diabetes were explored. In the present invention, American ginseng is the monarch medicine, nourishing qi and promoting body fluid, nourishing yin, moistening dryness and clearing heat, and treating diabetes with yin deficiency. Huangjing, Digupi, and Curcuma are the official medicines. Among them, Polygonatum is calm, invigorating qi and nourishing yin, moisturizing the lungs and nourishing the kidney, and helping American ginseng to invigorate Qi and invigorating body fluid; Digupi clears heat and cools blood, and Curcuma radices qi and breaks blood stasis. The spleen, Digupi and Curcuma are used together to clear away heat and cool blood to remove blood stasis, and to treat the symptoms of heat stasis. The Divine Comedy is used as an assistant, strengthens the spleen and stomach, digests food and dissolves accumulation, dispels accumulated heat in the stomach and intestines, and promotes the smooth flow of Qi. This recipe is refined and powerful, one drug has multiple effects, the compatibility is strict, and it is suitable for the pathogenesis. At the same time, all the medicines in this recipe have been verified by modern pharmacology to regulate blood sugar, lower lipids or improve hemodynamics. Divine Comedy can also improve intestinal flora imbalance.

本發明具有以下有益效果:本發明結合中藥萃取方法,將其與糞菌分離工藝進行深度融合,製成中藥配方菌群膠囊,在改變給藥方法的同時極 大地提高了治療效果,實現了高效、舒適的治療途徑。本發明的中藥配方與腸道菌群兩者結合製備成的中藥配方菌群膠囊,經臨床驗證表明,其治療效果顯著,兩者的結合具備互補功效,既彌補了中藥湯劑煎煮、服用的不便的缺點,也克服了菌群輸注時需通過腸鏡輔助給患者帶來的痛苦,幷且治療效果也得到明顯的提升。既滿足了人們適用、安全、有效的要求,又實現了人們環保、人性、方便的願望。 The present invention has the following beneficial effects: the present invention combines the traditional Chinese medicine extraction method, deeply integrates it with the fecal bacteria separation process, and prepares traditional Chinese medicine formula flora capsules. The treatment effect is greatly improved, and an efficient and comfortable treatment approach is realized. The traditional Chinese medicine formula of the present invention and the intestinal flora are prepared by combining the traditional Chinese medicine formula flora capsule. The clinical verification shows that the therapeutic effect is remarkable, and the combination of the two has complementary effects, which not only makes up for the decoction of traditional Chinese medicine, taking It also overcomes the inconvenient shortcomings of the colonoscopy, and overcomes the pain caused by colonoscopy to assist patients during bacterial infusion, and the treatment effect has also been significantly improved. It not only meets people's requirements for being applicable, safe and effective, but also realizes people's desire for environmental protection, humanity and convenience.

圖1為本發明采用的智能糞菌分離系統結構示意圖(即201410606325.4專利中圖1)。 FIG. 1 is a schematic structural diagram of the intelligent fecal bacteria separation system adopted in the present invention (ie, FIG. 1 in the 201410606325.4 patent).

圖2為本發明的無菌一次性耗材的結構示意圖。 FIG. 2 is a schematic structural diagram of the sterile disposable consumable of the present invention.

圖3為中藥萃取工藝的流程示意圖。 Figure 3 is a schematic flow diagram of the extraction process of traditional Chinese medicine.

圖4為本發明智能糞菌分離系統中不銹鋼濾網的結構示意圖。其中,A級為1.0mm、B級600μm、C級500μm、D級350μm、E級250μm、F級200μm、G級150μm、H級100μm、I級70μm、J級60μm、K級40μm。 4 is a schematic structural diagram of a stainless steel filter screen in the intelligent fecal bacteria separation system of the present invention. Among them, A grade is 1.0mm, B grade 600μm, C grade 500μm, D grade 350μm, E grade 250μm, F grade 200μm, G grade 150μm, H grade 100μm, I grade 70μm, J grade 60μm, K grade 40μm.

圖5為本發明中藥配方菌群工藝流程示意圖。 5 is a schematic diagram of the process flow diagram of the traditional Chinese medicine formula flora of the present invention.

圖6為中藥配方菌群膠囊配置液對2型糖尿病模型大鼠空腹血糖的影響。 Figure 6 shows the effect of the traditional Chinese medicine formula bacteria group capsule preparation solution on the fasting blood glucose of type 2 diabetes model rats.

圖7為中藥配方菌群膠囊配置液對2型糖尿病模型大鼠血清胰島素的影響。 Figure 7 shows the effect of the traditional Chinese medicine formula bacteria group capsule preparation liquid on the serum insulin of type 2 diabetes model rats.

圖8為兩組治療前後FBG的比較。 Figure 8 shows the comparison of FBG before and after treatment in the two groups.

圖9為兩組治療前後PBG的比較。 Figure 9 shows the comparison of PBG before and after treatment in the two groups.

圖10為兩組治療前後HbA1c的比較。 Figure 10 shows the comparison of HbA1c before and after treatment in the two groups.

下面通過具體實施方式的詳細描述來進一步闡明本發明,但幷不是對本發明的限制,僅僅作示例說明。 The present invention will be further clarified by the detailed description of the specific embodiments below, but it is not intended to limit the present invention, but only for illustration.

實施例1:提取菌群 Example 1: Extraction of flora

本發明使用智能糞菌分離系統配合一次性使用耗材組件自動分離提取,其中,智能糞菌分離系統是腔道內容物中微生物分離裝置,專利號為:ZL 201410606325.4,或者是糞便分析前處理儀,型號:FMT-5A-50/FMT-6A-50。一次性使用耗材包括過濾瓶3、分離物罐4、分裝瓶5、除臭裝置8、吸液除臭緩衝瓶11和菌液管路22等。 The present invention uses the intelligent fecal bacteria separation system to automatically separate and extract the disposable consumables components, wherein the intelligent fecal bacteria separation system is a device for separating microorganisms in the cavity contents, the patent number is: ZL 201410606325.4, or a fecal analysis preprocessor, Model: FMT-5A-50/FMT-6A-50. Disposable consumables include filter bottle 3, separator tank 4, sub-bottle 5, deodorization device 8, liquid absorption and deodorization buffer bottle 11, bacterial liquid pipeline 22, etc.

本發明的菌群提取方法主要步驟如下:用無菌原物罐(無菌一次性耗材,其結構如圖2所示)收集健康供者的糞便樣品200g,密封送至無菌操作室,配合過濾瓶3、分離物罐4、分裝瓶5、除臭裝置8、吸液除臭緩衝瓶11和菌液管路22等一同放置在智能糞菌分離系統中進行菌群收集。 The main steps of the bacterial flora extraction method of the present invention are as follows: collect 200 g of fecal samples from healthy donors with a sterile raw material tank (sterile disposable consumables, the structure of which is shown in Figure 2 ), seal it and send it to a sterile operating room, cooperate with a filter bottle 3 , separator tank 4, sub-bottling 5, deodorization device 8, liquid absorption and deodorization buffer bottle 11 and bacteria liquid pipeline 22, etc. are placed together in the intelligent fecal bacteria separation system for bacteria collection.

通過加液驅動裝置7將1000ml生理鹽水加注到采樣瓶中對糞便樣本進行浸泡,通過攪拌裝置對糞便樣本進行攪拌使其充分均質。 Add 1000ml of physiological saline into the sampling bottle to soak the stool sample through the liquid addition driving device 7, and stir the stool sample through the stirring device to make it fully homogenized.

打開氣泵二31將采樣瓶中的混合菌液依次通過A、B、C、D、E、F、J、H、I、J、K(具體數值詳見圖4)不同過濾值的過濾瓶3彙集到分裝瓶5中。在5℃條件下進行離心,離心後去掉上清液,保留沉澱,此沉澱即為分離純化後的菌液沉澱,總的重量約為100g。 Turn on the air pump 2 31 and pass the mixed bacterial liquid in the sampling bottle through A, B, C, D, E, F, J, H, I, J, K (see Figure 4 for specific values) in sequence through the filter bottles 3 with different filter values Pooled into sub-bottle 5. Centrifuge at 5°C, remove the supernatant after centrifugation, and retain the precipitate, which is the bacterial liquid precipitate after separation and purification, and the total weight is about 100 g.

向每個分裝瓶5中加入約10ml(12.6g)甘油,用振蕩器混勻,將其放入-80℃冰箱中預凍一小時。預凍完成後迅速將預凍後樣品移入菌液製備凍乾機(例如產品名稱:冷凍乾燥機,生產企業:寧波新芝生物科技股份有限公司,型號:scientz-18N)進行冷凍乾燥,壓力為0.006Pa,時間不低于10小時,將凍乾後的菌液脫水後得到菌群凍乾粉。 About 10 ml (12.6 g) of glycerol was added to each sub-bottle 5, mixed well with a shaker, and placed in a -80°C refrigerator to pre-freeze for one hour. Immediately after the pre-freezing is completed, the pre-frozen samples are transferred to a bacterial liquid preparation freeze-drying machine (for example, product name: freeze dryer, manufacturer: Ningbo Xinzhi Biotechnology Co., Ltd., model: scientz-18N) for freeze-drying, and the pressure is 0.006Pa, the time is not less than 10 hours, and the freeze-dried bacterial liquid is dehydrated to obtain the bacterial group freeze-dried powder.

實施例2:中藥萃取 Example 2: Chinese medicine extraction

用傳統濃縮提取法將中藥進行有效成份提取(中藥萃取工藝流程請參見圖3),具體方法如下:按重量比10:15:15:10:10的比例取藥材西洋參、黃精、神曲、地骨皮、莪術,適當地切碎或粉碎,置煎煮容器中。 The traditional Chinese medicine is extracted by the traditional concentrated extraction method (see Figure 3 for the process flow of Chinese medicine extraction). Bone skin, curcuma, properly chopped or crushed, and placed in a decoction container.

加適量水使浸沒藥材,浸泡適宜時間。 Add an appropriate amount of water to submerge the medicinal materials for a suitable time.

加熱至沸,浸出一定時間,分離煎出液,藥渣依法煎出2-3次,收集煎出液。 Heat to boiling, leaching for a certain period of time, separate the decoction liquid, decoct the medicinal residues 2-3 times according to the law, and collect the decoction liquid.

將水煎煮液蒸發至比重為1:1,冷後加入2倍乙醇,充分混勻,放置過夜,使其沉澱,次日濾過其清液,沉澱物用少量60%乙醇洗淨,洗液與濾液合幷,减壓回收乙醇後,濃縮至1g/ml濃度時移置放冷處(或加一定量水.混勻)靜置一定時間,使沉澱完全,濾過。 Evaporate the decoction liquid to a specific gravity of 1:1, add 2 times ethanol after cooling, mix well, leave it overnight to make it precipitate, filter the clear liquid the next day, wash the precipitate with a small amount of 60% ethanol, wash the liquid Combine it with the filtrate, recover ethanol under reduced pressure, and when concentrated to a concentration of 1 g/ml, place it in a cold place (or add a certain amount of water and mix it) and let it stand for a certain period of time to make the precipitation complete and filter.

濾液用真空烘乾機烘乾,烘乾後再用超微粉碎機對其進行粉碎加工,得到10μm超細粉。 The filtrate is dried with a vacuum dryer, and then pulverized with an ultrafine pulverizer after drying to obtain a 10 μm ultrafine powder.

實施例3:製備中藥配方菌群膠囊 Embodiment 3: prepare traditional Chinese medicine formula flora capsule

中藥配方菌群工藝流程見圖5,將實施例1中的菌群凍乾粉,與實施例2中萃取後的中藥萃取粉,按體積比1:1的比例混合後用微型攪拌機攪拌混勻制得中藥配方菌群,幷用耐酸羥丙甲纖維素膠囊灌裝,每粒膠囊含有中藥粉末1.5克,菌粉1.5克,再用密封包裝袋包裝後在-20℃冰箱中儲藏。 The process flow of traditional Chinese medicine formula flora is shown in Figure 5. The freeze-dried powder of the flora in Example 1 and the extracted traditional Chinese medicine powder in Example 2 are mixed in a volume ratio of 1:1 and mixed with a micro mixer. The traditional Chinese medicine formula flora is prepared and filled with acid-resistant hypromellose capsules. Each capsule contains 1.5 grams of traditional Chinese medicine powder and 1.5 grams of bacterial powder, and is then packed in a sealed bag and stored in a -20°C refrigerator.

實施例4:中藥配方菌群膠囊對2型糖尿病模型大鼠的治療作用 Embodiment 4: Therapeutic effect of traditional Chinese medicine formula bacteria group capsules on type 2 diabetes model rats

通過實驗研究,探討本發明中藥配方菌群膠囊對2型糖尿病模型大鼠糖脂代謝及胰島素抵抗的影響。 Through experimental research, the effects of the traditional Chinese medicine formula bacteria capsules of the present invention on glucose and lipid metabolism and insulin resistance in type 2 diabetes model rats are discussed.

1 實驗材料 1 Experimental material

1.1 實驗動物 1.1 Experimental animals

SPF級SD雄性大鼠40只,體重200±20克,8周齡。每籠5只分籠飼養。濕度40%-60%,室溫16-26℃。普通飼料喂養,自由進食進水,天黑前喂食。動態觀察大鼠的進食量和飲水量,每周稱體重一次。更換籠子墊料每日一次。 Forty male SD rats of SPF grade, weighing 200±20 g, were 8 weeks old. 5 per cage were kept in separate cages. Humidity 40%-60%, room temperature 16-26℃. Common feed, free food and water, feeding before dark. The food intake and water intake of the rats were dynamically observed, and the body weight was weighed once a week. Change cage litter once a day.

1.2 藥物與試劑 1.2 Drugs and Reagents

實施例3中制得的中藥配方菌群膠囊,使用時配成的濃度為2.1g/ml,此為能够通過大鼠灌胃器的最大濃度藥液。 The concentration of the traditional Chinese medicine formula bacteria capsules prepared in Example 3 is 2.1 g/ml when used, which is the maximum concentration medicinal liquid that can pass through the rat gastric gavage device.

吡格列酮(瑞彤,15mg/片,江蘇恒瑞醫藥有限公司,國藥准字:H20040631)。 Pioglitazone (Ruitong, 15mg/tablet, Jiangsu Hengrui Pharmaceutical Co., Ltd., approved by Chinese medicine: H20040631).

鏈脲佐菌素(STZ)(美國sigma公司產品)。葡萄糖測定試劑盒(上海榮盛生物藥業有限公司),胰島素ELISA試劑盒(英國R&G公司生產,上海元象醫療器械有限公司分裝)。枸櫞酸三鈉、枸櫞酸、戊巴比妥鈉。 Streptozotocin (STZ) (product of American sigma company). Glucose determination kit (Shanghai Rongsheng Bio-Pharmaceutical Co., Ltd.), insulin ELISA kit (produced by R&G Company in the United Kingdom, subpackaged by Shanghai Yuanxiang Medical Equipment Co., Ltd.). Trisodium citrate, citric acid, pentobarbital sodium.

1.3 高糖高脂飼料配方 1.3 High-sugar and high-fat feed formula

膽固醇、猪油、蔗糖、蛋黃粉、普通飼料。 Cholesterol, lard, sucrose, egg yolk powder, common feed.

1.4 主要儀器和器材 1.4 Main instruments and equipment

血糖儀及血糖試紙(强生醫療器材公司),全自動免疫濁度分析儀。臺式離心機,注射器若干,試管,燒杯和量筒若干,精密電子天平,電子秤,錫箔紙等。 Blood glucose meter and blood glucose test strip (Johnson & Johnson Medical Equipment Company), automatic immune turbidity analyzer. Desktop centrifuges, several syringes, test tubes, beakers and measuring cylinders, precision electronic balances, electronic scales, tin foil, etc.

2 實驗方法 2 Experimental methods

2.1 模型製作 2.1 Model making

適應性喂養1周後,隨機分為正常對照組(10只)和造模組(30只),正常對照組喂養普通飼料,造模組喂養高糖高脂飼料6周後,予造模組大鼠腹腔內單次注射鏈脲佐菌素(STZ,30mg/kg),正常對照組(A組)單次注射等量枸櫞酸緩衝液,72h後采血,用强生公司的SureStepPlus血糖儀測定全血血糖,血糖

Figure 110120881-A0305-02-0010-4
16.7mmol/L確定為2型糖尿病大鼠模型。 After 1 week of adaptive feeding, they were randomly divided into a normal control group (10 animals) and a modeling group (30 animals). Rats were injected intraperitoneally with streptozotocin (STZ, 30mg/kg), and the normal control group (group A) was injected with the same amount of citrate buffer, blood was collected 72 hours later, and measured with the SureStepPlus blood glucose meter of Johnson & Johnson blood glucose, blood sugar
Figure 110120881-A0305-02-0010-4
16.7mmol/L was identified as type 2 diabetes rat model.

2.2 動物分組與給藥 2.2 Animal grouping and administration

成模後將成模大鼠隨機分為模型對照組(B組)、吡格列酮組(C組)、中藥配方菌群組(D組)各10只。另設正常對照組(A組)10只。將C組給予吡格列酮2.5g/kg‧d灌胃,D組給予中藥配方菌群膠囊配置液12g/kg‧d灌胃;A與B組給予等量生理鹽水灌胃。給藥體積為10ml/kg體重,每日1次,固定時間給藥,連續給藥8周。 After the model was established, the model rats were randomly divided into model control group (group B), pioglitazone group (group C), and traditional Chinese medicine formula bacteria group (group D), 10 rats each. Another 10 normal control group (group A) were set up. Group C was given pioglitazone 2.5 g/kg·d by gavage, group D was given 12 g/kg·d of traditional Chinese medicine formula microflora capsules by gavage; groups A and B were given the same amount of normal saline by gavage. The administration volume was 10ml/kg body weight, once a day, administered at a fixed time, and administered continuously for 8 weeks.

實驗期間均不限制進食及飲水,不使用胰島素及其他降糖藥物。 During the experiment, food and water were not restricted, and insulin and other hypoglycemic drugs were not used.

2.3 血液標本收集 2.3 Blood Specimen Collection

于造模前以及灌胃給藥後8周末次日處死大鼠,處死前禁食12小時,測定體重、體長及尾長;眼眶采血標本,備測胰島素和血糖等生化指標。 Rats were sacrificed before modeling and the next day after 8 weeks after oral administration. Fasting for 12 hours before sacrifice, body weight, body length and tail length were measured; orbital blood samples were collected to prepare biochemical indicators such as insulin and blood sugar.

2.4 生化及免疫等指標檢測 2.4 Detection of biochemical and immune indicators

血糖用全自動生化分析儀檢測。所有測定項目均嚴格按照試劑盒說明書操作。 Blood sugar was detected with an automatic biochemical analyzer. All assay items were operated in strict accordance with the kit instructions.

2.5 統計學處理 2.5 Statistical processing

觀察和比較各組不同時段各個觀察指標的變化情况,幷采用SPSS for Windows 22.0統計學軟件進行假設檢驗和相關性分析。所有計量資料數據以均值±標準差(±SD)表示,兩組間及前後比較用t檢驗,多組間比較用方差分析(Oneway-ANOVA)。P<0.05為差异有統計學意義。 Observe and compare the changes of each observation index in each group at different time periods, and use SPSS for Windows 22.0 statistical software for hypothesis testing and correlation analysis. All measurement data are expressed as mean±standard deviation (±SD), t-test was used for comparison between two groups and before and after, and analysis of variance (Oneway-ANOVA) was used for comparison between multiple groups. P<0.05 means the difference is statistically significant.

實驗結果 Experimental results

1 中藥配方菌群膠囊配置液對模型大鼠空腹血糖的影響 1 Effects of traditional Chinese medicine formula bacteria group capsules on fasting blood sugar in model rats

治療後中藥配方菌群組、吡格列酮組空腹血糖與治療前比較均有顯著性差异(p<0.01),治療後中藥配方菌群組、吡格列酮組空腹血糖與模型組組間比較,也均有顯著性差异(p<0.01)。結果見表1、圖6。 After treatment, the fasting blood glucose of the traditional Chinese medicine formula bacteria group and the pioglitazone group were significantly different from those before treatment (p<0.01). Sexual differences (p<0.01). The results are shown in Table 1 and Figure 6.

表1:中藥配方菌群膠囊配置液對2型糖尿病模型大鼠空腹血糖的影響(

Figure 110120881-A0305-02-0011-5
±s)
Figure 110120881-A0305-02-0012-1
Table 1: Influence of traditional Chinese medicine formula bacteria group capsule configuration liquid on fasting blood glucose of type 2 diabetes model rats (
Figure 110120881-A0305-02-0011-5
±s)
Figure 110120881-A0305-02-0012-1

2 中藥配方菌群膠囊配置液對模型大鼠血清空腹胰島素的影響 2 The effect of traditional Chinese medicine formula bacteria group capsules on serum fasting insulin in model rats

治療後中藥配方菌群組及吡格列酮組大鼠血清空腹胰島素水平與治療前比較有明顯上升,有統計學意義(P<0.01),兩組與2型糖尿病模型組組間比較,也均有顯著性差异(P<0.01)。結果見表2、圖7。 After treatment, the serum fasting insulin levels of the Chinese medicine formula bacteria group and pioglitazone group were significantly increased compared with those before treatment, with statistical significance (P<0.01). Sex difference (P<0.01). The results are shown in Table 2 and Figure 7.

Figure 110120881-A0305-02-0012-2
Figure 110120881-A0305-02-0012-2

實驗結果分析:動物實驗表明,中藥配方菌群組治療後空腹血糖與治療前比較有顯著性差异(p<0.01),與模型組比較也有顯著性差异(p<0.01)。提示中藥配方菌群膠囊具有降低血糖的作用。 Analysis of experimental results: Animal experiments showed that the fasting blood glucose of the traditional Chinese medicine formula group after treatment was significantly different from that before treatment (p<0.01), and there was also a significant difference compared with the model group (p<0.01). It is suggested that the traditional Chinese medicine formula microflora capsule has the effect of lowering blood sugar.

中藥配方菌群組大鼠治療後空腹血清胰島素水平與治療前比較有所上升,有統計學意義(P<0.01),與模型組比較也有顯著性差异(P<0.01)。提示中 藥配方菌群膠囊具有促進胰島素分泌、提高空腹胰島素水平的作用,其可能通過此作用達到降低血糖的結果。 Compared with before treatment, the fasting serum insulin level of the rats in the traditional Chinese medicine formula bacteria group increased, which was statistically significant (P<0.01), and there was also a significant difference compared with the model group (P<0.01). prompt The medicinal formula microflora capsule has the effect of promoting insulin secretion and increasing the level of fasting insulin, which may achieve the result of lowering blood sugar through this effect.

實施例5:中藥配方菌群膠囊對2型糖尿病的臨床療效觀察 Embodiment 5: Clinical observation of the clinical efficacy of traditional Chinese medicine formula bacteria capsules on type 2 diabetes mellitus

為了驗證本發明中藥配方菌群膠囊治療2型糖尿病的效果,我們抽取了60名患者進行了中藥配方菌群膠囊(實施例3中制得的中藥配方菌群膠囊)(治療2型糖尿病的臨床觀察,將所有患者隨機分為兩組,其中治療組30例,對照組30例。治療前兩組患者在性別、年齡、病程、體重指數等方面經統計學分析均無顯著性差异,具有可比性。 In order to verify the effect of the traditional Chinese medicine formula bacteria group capsule of the present invention in treating type 2 diabetes, we selected 60 patients to carry out the traditional Chinese medicine formula bacteria group capsule (the traditional Chinese medicine formula bacteria group capsule prepared in Example 3) (the clinical treatment of type 2 diabetes mellitus). All patients were randomly divided into two groups, including 30 cases in the treatment group and 30 cases in the control group. Before treatment, there was no significant difference in gender, age, course of disease, body mass index, etc. between the two groups of patients, and they were comparable. sex.

1、治療方案 1. Treatment plan

兩組病人均進行常規的基礎治療,包括健康教育、飲食控制、有規律的運動。 Both groups received routine basic treatment, including health education, diet control, and regular exercise.

對照組:基礎治療+常規西藥(按《中國2型糖尿病防治指南(2010年版)》)治療。 Control group: basic treatment + conventional western medicine (according to "Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2010 Edition)").

治療組:基礎治療+常規西藥(按《中國2型糖尿病防治指南(2010年版)》)治療+中藥配方菌群膠囊,每日2次,每次20粒。 Treatment group: basic treatment + conventional western medicine (according to "China's Guidelines for the Prevention and Treatment of Type 2 Diabetes (2010 Edition)") + traditional Chinese medicine formula microflora capsules, 20 capsules each time, 2 times a day.

兩組均以4周為1個療程,觀察3個療程。 The two groups were treated for 4 weeks as a course of treatment, and three courses of treatment were observed.

2、西醫診斷標準: 2. Western medicine diagnostic criteria:

(1)糖尿病[依據1999年世界衛生組織(WHO)制定的糖尿病診斷標準]。 (1) Diabetes mellitus [according to the 1999 World Health Organization (WHO) diagnostic criteria for diabetes].

Figure 110120881-A0305-02-0013-6
有明顯DM“三多一少”等症狀,隨機血糖
Figure 110120881-A0305-02-0013-7
11.1mmol/L(200mg/dl);
Figure 110120881-A0305-02-0013-8
空腹靜脉血漿糖
Figure 110120881-A0305-02-0013-10
7.0mmol/L(126mg/dl);
Figure 110120881-A0305-02-0013-9
OGTT(口服75g葡萄糖)2小時PG
Figure 110120881-A0305-02-0013-11
11.1mmol/L(200mg/dl)
Figure 110120881-A0305-02-0013-6
There are obvious DM symptoms such as "three more and one less", random blood sugar
Figure 110120881-A0305-02-0013-7
11.1mmol/L (200mg/dl);
Figure 110120881-A0305-02-0013-8
fasting venous plasma glucose
Figure 110120881-A0305-02-0013-10
7.0mmol/L (126mg/dl);
Figure 110120881-A0305-02-0013-9
OGTT (oral 75g glucose) 2 hours PG
Figure 110120881-A0305-02-0013-11
11.1mmol/L(200mg/dl)

以上三條,單獨符合一條,均可作為診斷依據和標準,但要求隔一段時間複查結果仍符合診斷標準時,診斷可確立。 The above three items, if they meet one of them individually, can be used as the diagnostic basis and standard, but the diagnosis can be established if the results of the reexamination after a period of time still meet the diagnostic criteria.

(2)2型糖尿病診斷標準 (2) Diagnostic criteria for type 2 diabetes

參照1997年7月Diabetes Care雜志上刊登的糖尿病病因學分型標準,凡符合糖尿病的診斷標準,胰島素釋放試驗結果符合下述條件之一者即診斷為2型糖尿病。 With reference to the diabetes etiology classification criteria published in the journal Diabetes Care in July 1997, those who meet the diagnostic criteria for diabetes and the insulin release test results that meet one of the following conditions are diagnosed as type 2 diabetes.

Figure 110120881-A0305-02-0014-12
以胰島素抵抗為主伴相對胰島素不足。
Figure 110120881-A0305-02-0014-12
Insulin resistance is predominant with relative insulin insufficiency.

Figure 110120881-A0305-02-0014-13
胰島素明顯缺乏伴胰島素抵抗。
Figure 110120881-A0305-02-0014-13
Insulin deficiency is marked with insulin resistance.

3、納入標準 3. Inclusion criteria

(1)年齡在十八歲至六十五歲之間;(2)知情同意;(3)符合2型糖尿病診斷標準;(4)性別不限。 (1) Aged between 18 and 65 years old; (2) Informed consent; (3) Meet the diagnostic criteria for type 2 diabetes; (4) Any gender.

4、排除標準 4. Exclusion criteria

(1)T1DM、懷孕、藥物等因素引起的血糖升高;(2)未按規定服藥,無法判斷療效或資料不全等影響療效判斷者;(3)正在參加其他藥物臨床研究的患者。 (1) Elevated blood sugar caused by factors such as T1DM, pregnancy, drugs, etc.; (2) Those who fail to take medicines as prescribed, unable to judge the efficacy or incomplete data, etc., which affect the judgment of efficacy; (3) Patients who are participating in clinical studies of other drugs.

5、治療前後兩組血糖、糖化血紅蛋白的變化 5. Changes of blood glucose and glycosylated hemoglobin in the two groups before and after treatment

治療前兩組血糖、糖化血紅蛋白比較,無明顯差异(P>0.05),具有可比性。治療後治療組與對照組患者空腹血糖、餐後血糖均明顯降低,與治療前比較均有顯著性差异(P<0.01);治療組治療後空腹血糖改善較對照組有顯著差异(P<0.01),治療組餐後血糖改善較對照組有差异(P<0.05),治療組糖化血紅蛋白的改善較對照組有差异(P<0.05)。見表3、圖8、圖9、圖10。 There was no significant difference in blood glucose and glycosylated hemoglobin between the two groups before treatment (P>0.05), which was comparable. After treatment, the fasting blood sugar and postprandial blood sugar in the treatment group and the control group were significantly decreased, and there were significant differences compared with those before treatment (P<0.01). ), the improvement of postprandial blood glucose in the treatment group was different from that in the control group (P<0.05), and the improvement of glycosylated hemoglobin in the treatment group was different from that in the control group (P<0.05). See Table 3, Figure 8, Figure 9, Figure 10.

表3:兩組治療前後FBG、PBG、HbA1c的比較

Figure 110120881-A0305-02-0015-3
Table 3: Comparison of FBG, PBG, HbA1c between the two groups before and after treatment
Figure 110120881-A0305-02-0015-3

6、結果分析 6. Result analysis

治療後治療組與對照組患者空腹血糖、餐後血糖、糖化血紅蛋白均明顯降低,較對照組有差异(P<0.05或P<0.01),說明常規西藥+中藥配方菌群膠囊對2型糖尿病血糖的改善作用優于單獨使用常規西藥控制血糖的作用。 After treatment, fasting blood sugar, postprandial blood sugar, and glycosylated hemoglobin in the treatment group and the control group were significantly decreased, and there was a difference compared with the control group (P<0.05 or P<0.01), indicating that conventional western medicine + traditional Chinese medicine formula bacteria group capsules can significantly reduce blood sugar in type 2 diabetes. The improvement effect is better than that of using conventional western medicine alone to control blood sugar.

實施例6:臨床病例 Example 6: Clinical case

根據實施例5的臨床療效觀察中的典型病例提供如下。即病例的治療方案是:每次服用20粒,每日2次;每4周為1個療程;治療三個療程。 Typical cases in the clinical efficacy observation according to Example 5 are provided as follows. That is, the treatment plan of the case is: take 20 capsules each time, 2 times a day; every 4 weeks is a course of treatment; three courses of treatment are treated.

病例1: Case 1:

患者張某,男,72歲,“2型糖尿病”史30餘年,曾口服“格列齊特30mgqd、阿卡波糖50mg tid”控制血糖,血糖控制不佳,後加用“沙格列汀5mg qd”,空腹血糖控制在8.5-9.5mmol/l,餐後血糖10-12mmol/l,糖化血紅蛋白7-7.5%。口乾多飲明顯,偏胖,大便偏乾,易疲勞,口苦,舌紅苔黃,脉弦細。服用本發明中藥配方菌群膠囊,治療三個療程,口乾口苦、疲勞乏力明顯改善,大便每日一次。空腹血糖控制在7mmol/l左右,餐後血糖8mmol/l左右,糖化血紅蛋白6.8%。 The patient Zhang, male, 72 years old, has a history of "type 2 diabetes" for more than 30 years. He has taken oral "gliclazide 30mgqd, acarbose 50mg tid" to control blood sugar, but the blood sugar control is not good, and then "saxagliptin" is added. 5mg qd", fasting blood sugar is controlled at 8.5-9.5mmol/l, postprandial blood sugar is 10-12mmol/l, and glycosylated hemoglobin is 7-7.5%. Obvious dry mouth and polydipsia, fat, dry stool, easy fatigue, bitter mouth, red tongue and yellow coating, thin pulse. Taking the traditional Chinese medicine formula microflora capsule of the present invention for three courses of treatment, the dry mouth and bitter taste, fatigue and fatigue are obviously improved, and the stool is once a day. The fasting blood sugar is controlled at about 7mmol/l, the postprandial blood sugar is about 8mmol/l, and the glycated hemoglobin is 6.8%.

病例2: Case 2:

患者王某某,女,69歲,“2型糖尿病”史18年,曾口服“二甲雙胍500mg tid”控制血糖,後因消化道症狀明顯,改用“沙格列汀5mg qd、瑞格列奈1mg tid”,空腹血糖控制在9-10mmol/l,餐後血糖9-12mmol/l,糖化血紅蛋白8.5%左右,血糖波動大,曾發生低血糖反應,後不敢過度控制飲食。多食易饑明顯,腹脹,大便乾稀不調,容易便溏,易疲勞,口乾,舌紅苔少,脉細數。服用本發明中藥配方菌群膠囊,治療三個療程,饑餓感明顯减輕,腹脹、大便情况明顯改善,空腹血糖控制在6-9mmol/l,餐後血糖10mmol/l左右,糖化血紅蛋白7.8%。 The patient Wang Moumou, female, 69 years old, has a history of "type 2 diabetes" for 18 years. She used to take "metformin 500mg tid" orally to control blood sugar. Later, due to obvious gastrointestinal symptoms, she switched to "saxagliptin 5mg qd, repaglinide" 1mg tid", fasting blood sugar is controlled at 9-10mmol/l, postprandial blood sugar is 9-12mmol/l, glycosylated hemoglobin is about 8.5%, blood sugar fluctuates greatly, hypoglycemia reaction has occurred, and then dare not control diet excessively. Excessive food and easy hunger, abdominal distension, loose stools, easy to loose stools, easy fatigue, dry mouth, red tongue with little coating, thin pulse. Taking the traditional Chinese medicine formula microflora capsule of the present invention for three courses of treatment, the hunger is obviously relieved, the abdominal distension and the stool condition are obviously improved, the fasting blood sugar is controlled at 6-9 mmol/l, the postprandial blood sugar is about 10 mmol/l, and the glycosylated hemoglobin is 7.8%.

病例3: Case 3:

患者陸某,男,56歲,“2型糖尿病”史10年,口服“二甲雙胍、沙格列汀”控制血糖,空腹血糖控制在8-10mmol/l,餐後血糖9-11mmol/l,糖化血紅蛋白7.7%,口乾多飲,易腹脹,容易便溏。服用本發明中藥配方菌群膠囊,治療三個療程,口乾、腹脹、大便情况明顯改善,幷停用二甲雙胍,空腹血糖控制在6-7mmol/l,餐後血糖9mmol/l左右,糖化血紅蛋白7.1%。 The patient Lu, male, 56 years old, has a history of "type 2 diabetes" for 10 years. He takes "metformin and saxagliptin" to control blood sugar, fasting blood sugar is controlled at 8-10mmol/l, postprandial blood sugar is 9-11mmol/l, glycation Hemoglobin 7.7%, dry mouth and polydipsia, easy abdominal distension and loose stools. Taking the traditional Chinese medicine formula microflora capsules of the present invention for three courses of treatment, the dry mouth, abdominal distension, and stool conditions were significantly improved, and metformin was stopped, the fasting blood sugar was controlled at 6-7mmol/l, the postprandial blood sugar was about 9mmol/l, and the glycosylated hemoglobin was 7.1. %.

病例4: Case 4:

患者金某某,男,81歲,“2型糖尿病”史30餘年,曾口服多種降糖藥控制血糖,但控制不佳,5年前改用“諾和靈30R早26u晚12u”聯合“西格列汀100mg qd”控制血糖,空腹血糖控制在7-10mmol/l,餐後血糖8-14mmol/l,糖化血紅蛋白7.5%左右,血糖波動大,飲食控制差,容易焦慮,運動少,腹脹,大便2-3日一行,舌紅苔黃,脉弦。服用本發明中藥配方菌群膠囊,治療三個療程,症狀明顯改善,空腹血糖控制在6-9mmol/l,餐後血糖9-10mmol/l左右,糖化血紅蛋白6.4%。胰島素每日用量减少4u。 The patient Jin Moumou, male, 81 years old, has a history of "type 2 diabetes" for more than 30 years. He has taken a variety of oral hypoglycemic drugs to control blood sugar, but the control is not good. Sitagliptin 100mg qd" controls blood sugar, fasting blood sugar is controlled at 7-10mmol/l, postprandial blood sugar is 8-14mmol/l, glycosylated hemoglobin is about 7.5%, blood sugar fluctuates greatly, diet control is poor, easy to be anxious, less exercise, abdominal distension , stool 2-3 days a line, red tongue, yellow coating, pulse string. Taking the traditional Chinese medicine formula microflora capsule of the present invention for three courses of treatment, the symptoms are obviously improved, the fasting blood sugar is controlled at 6-9 mmol/l, the postprandial blood sugar is about 9-10 mmol/l, and the glycosylated hemoglobin is 6.4%. The daily dose of insulin is reduced by 4u.

病例5: Case 5:

患者李某某,男,43歲,“2型糖尿病”史3年,口服“二甲雙胍1000mg/日”控制血糖,空腹血糖良好,糖化血紅蛋白6.5%,但消化道症狀明顯, 腹脹,易便溏,舌淡紅有齒痕,苔白膩。因血糖控制較滿意,暫時不願意更換降糖藥,服用本發明中藥配方菌群膠囊,治療三個療程,腹脹、便溏改善,幷停用二甲雙胍,糖化血紅蛋白6.0%。 The patient Li Moumou, male, 43 years old, has a history of "type 2 diabetes" for 3 years. He took "metformin 1000 mg/day" to control blood sugar, his fasting blood sugar was good, his glycosylated hemoglobin was 6.5%, but his gastrointestinal symptoms were obvious. Abdominal distension, easy loose stool, pale red tongue with tooth marks, white and greasy fur. Because blood sugar control is relatively satisfactory, temporarily unwilling to replace hypoglycemic drugs, taking the traditional Chinese medicine formula microflora capsule of the present invention for three courses of treatment, abdominal distension and loose stools are improved, and metformin is stopped, and the glycosylated hemoglobin is 6.0%.

病例6: Case 6:

患者林某,男,76歲,“2型糖尿病”史20年,平時使用“甘精胰島素皮下注射18u/日”+“阿卡波糖口服150mg/日”控制血糖,空腹血糖控制在6-8mmol/l,餐後血糖8-12mmol/l,早餐後2小時血糖11mmol/l左右,其餘時段血糖控制尚可,糖化血紅蛋白7.2%,口乾多飲,大便乾稀不調,粘馬桶,舌紅質乾少苔,脉細弦。服用本發明中藥配方菌群膠囊,治療三個療程,口乾、大便情况明顯改善,自訴身體輕鬆,早餐後血糖7-10mmol/l,糖化血紅蛋白7%。 The patient Lin, male, 76 years old, has a history of "type 2 diabetes" for 20 years. He usually uses "subcutaneous insulin glargine injection 18u/day" + "acarbose oral 150mg/day" to control blood sugar, and fasting blood sugar is controlled at 6- 8 mmol/l, postprandial blood glucose 8-12 mmol/l, 2 hours after breakfast, blood glucose is about 11 mmol/l, the rest of the time blood glucose control is acceptable, glycated hemoglobin is 7.2%, dry mouth and polydipsia, loose stools, sticky toilet, red tongue Dry quality with little moss, thin and stringy pulse. Taking the traditional Chinese medicine formula microflora capsules of the present invention for three courses of treatment, the dry mouth and stool are obviously improved, the body is relaxed, the blood sugar after breakfast is 7-10 mmol/l, and the glycosylated hemoglobin is 7%.

病例7: Case 7:

患者李某,男,51歲,診斷“2型糖尿病”1個月,體檢時發現血糖升高,空腹達12mmol/l,至醫院系統檢查,診斷“2型糖尿病”,糖化血紅蛋白9.8%,口渴明顯,當時給予“諾和銳30早22u晚10u皮下注射”聯合“沙格列汀5mg/日”控制血糖,以及配合本發明中藥配方菌群膠囊,治療三個療程,血糖控制較好,治療三個療程,口渴明顯改善,糖化血紅蛋白6.4%。 The patient Li, male, 51 years old, was diagnosed with "type 2 diabetes" for 1 month. During the physical examination, it was found that the blood sugar was elevated, and the fasting amount was 12mmol/l. The thirst was obvious. At that time, "Novo Rui 30 early 22u evening 10u subcutaneous injection" was given in combination with "saxagliptin 5mg/day" to control blood sugar, and cooperated with the traditional Chinese medicine formula flora capsule of the present invention for three courses of treatment, and blood sugar control was better, After three courses of treatment, the thirst was significantly improved, and the glycated hemoglobin was 6.4%.

病例8: Case 8:

患者張某,女,70歲,診斷“2型糖尿病”8年,平時使用“瑞格列奈1mg tid”+“沙格列汀5mg qd”控制血糖,空腹血糖控制在7-8mmol/l,餐後血糖8-11mmol/l,糖化血紅蛋白7.3%,口乾多飲,大便乾稀不調,舌紅少苔,脉細弦。配合服用本發明中藥配方菌群膠囊,治療三個療程,口乾、大便情况明顯改善,空腹血糖6-8mmol/l,餐後血糖7-9mmol/l,糖化血紅蛋白6.4%。 Patient Zhang, female, 70 years old, diagnosed with "type 2 diabetes" for 8 years, usually uses "Repaglinide 1mg tid" + "saxagliptin 5mg qd" to control blood sugar, fasting blood sugar is controlled at 7-8mmol/l, Postprandial blood glucose is 8-11mmol/l, glycosylated hemoglobin is 7.3%, dry mouth and polydipsia, loose stools, red tongue with little coating, and thin pulse. Combined with taking the traditional Chinese medicine formula microflora capsule of the present invention for three courses of treatment, the dry mouth and stool are obviously improved, the fasting blood sugar is 6-8 mmol/l, the postprandial blood sugar is 7-9 mmol/l, and the glycosylated hemoglobin is 6.4%.

病例9: Case 9:

患者魯某某,女,81歲,診斷“2型糖尿病”近40年,平時使用“諾和銳30早26u晚14u”皮下注射控制血糖,但飲食不規律,喜吃零食,故血糖控制不佳,波動大,7-16mmol/l之間,飲食控制難,糖化血紅蛋白8.4%,有“糖尿病視網膜病變、周圍神經病變”幷發症,口乾多飲,易腹脹,手脚麻木,視物不清,皮膚瘙癢,記憶力下降,易口腔潰瘍,大便秘結,舌紅苔薄黃,脉弦。指導胰島素規範使用,進食較多或血糖較高時調整注射劑量,配合服用本發明中藥配方菌群膠囊,治療三個療程,口乾、視物不清、皮膚瘙癢改善,大便通暢,唯飲食習慣難以改變,血糖7-11mmol/l,糖化血紅蛋白7%。 The patient Lu Moumou, female, 81 years old, has been diagnosed with "type 2 diabetes" for nearly 40 years. He usually uses "Novo Rui 30 in the morning, 26 in the evening and 14 in the evening" to control blood sugar. Good, fluctuating, between 7-16mmol/l, difficult to control diet, glycosylated hemoglobin 8.4%, co-morbidities of "diabetic retinopathy and peripheral neuropathy", dry mouth and polydipsia, easy abdominal distension, numbness of hands and feet, poor vision Clear, itchy skin, memory loss, easy mouth ulcers, constipation, red tongue, thin yellow coating, stringy pulse. Instruct insulin to use in a standardized way, adjust the injection dose when eating more or when blood sugar is high, and take the traditional Chinese medicine formula flora capsule of the present invention for three courses of treatment. Difficult to change, blood sugar 7-11mmol/l, glycated hemoglobin 7%.

病例10: Case 10:

患者南某,男,50歲,診斷“2型糖尿病”12年,平時使用“甘精胰島素20u/日皮下注射”+“諾和龍三餐前1mg口服”控制血糖,有“消化不良”,易腹脹,2年前考慮有“胃輕癱”可能,血糖波動在6-13mmol/l之間,進食較多不消化食物,則腹脹、甚至嘔吐,大便不規律,1-4日一行,時乾時稀,舌淡紅有齒痕,苔白膩,脉弱。指導規律飲食,幷配合服用本發明中藥配方菌群膠囊,治療三個療程,腹脹明顯好轉,不再嘔吐,大便明顯改善,血糖6-11mmol/l,糖化血紅蛋白7.5%。 The patient Nan, male, 50 years old, has been diagnosed with "type 2 diabetes" for 12 years. He usually uses "insulin glargine 20u/day subcutaneous injection" + "Nuohelong 1 mg orally before three meals" to control blood sugar, and has "indigestion". Abdominal distension, the possibility of "gastroparesis" was considered 2 years ago, blood sugar fluctuated between 6-13mmol/l, eating a lot of undigested food, then abdominal distension, even vomiting, irregular stool, every 1-4 days, dry from time to time When thin, the tongue is reddish with tooth marks, the coating is white and greasy, and the pulse is weak. Instructing regular diet, and cooperating with taking the traditional Chinese medicine formula flora capsule of the present invention, for three courses of treatment, abdominal distension is obviously improved, no vomiting, stool is obviously improved, blood sugar is 6-11mmol/l, and glycosylated hemoglobin is 7.5%.

病例11: Case 11:

患者陳某某,女,67歲,診斷“2型糖尿病”近20年,曾口服降糖藥治療,後因血糖控制不佳,現使用“甘精胰島素14u/日皮下注射”+“阿卡波糖三餐前50mg嚼服”控制血糖,因每日注射胰島素,心情焦慮,空腹血糖7mmol/l左右,餐後血糖9-10mmol/l,糖化血紅蛋白8%,配合服用本發明中藥配方菌群膠囊,治療三個療程,心情焦慮好轉,甘精胰島素用量减至10u/日,空腹血糖7mmol/l左右,餐後血糖7-9mmol/l,糖化血紅蛋白7.5%。 Patient Chen Moumou, female, 67 years old, has been diagnosed with "type 2 diabetes" for nearly 20 years. She has been treated with oral hypoglycemic drugs, but due to poor blood sugar control, she is now using "insulin glargine 14u/day subcutaneous injection" + "Aka" 50mg of Botang before three meals to control blood sugar, due to daily insulin injection, anxiety, fasting blood sugar about 7mmol/l, postprandial blood sugar 9-10mmol/l, glycated hemoglobin 8%, in conjunction with taking the traditional Chinese medicine formula flora of the present invention Capsules, after three courses of treatment, anxiety improved, insulin glargine dosage was reduced to 10u/day, fasting blood sugar was about 7mmol/l, postprandial blood sugar was 7-9mmol/l, and glycosylated hemoglobin was 7.5%.

病例12: Case 12:

患者張某某,男,37歲,體檢發現血糖升高,後診斷“2型糖尿病”,發現時空腹血糖7.2mmol/l,餐後血糖10.0mmol/l,糖化血紅蛋白7.8%,多食易饑,口乾,指導飲食控制、適量運動,服用本發明中藥配方菌群膠囊,治療三個療程,多食易饑,口乾改善,空腹血糖6.5mmol/l左右,餐後血糖8.0mmol/l左右,糖化血紅蛋白7.3%。 The patient Zhang Moumou, male, 37 years old, was found to have elevated blood sugar on physical examination, and was later diagnosed with "type 2 diabetes". When found, fasting blood sugar was 7.2 mmol/l, postprandial blood sugar was 10.0 mmol/l, and glycosylated hemoglobin was 7.8%. , dry mouth, guide diet control, exercise in moderation, take traditional Chinese medicine formula flora capsules of the present invention, treat three courses of treatment, eat more and cause hunger, improve dry mouth, fasting blood sugar is about 6.5mmol/l, and postprandial blood sugar is about 8.0mmol/l , Glycated hemoglobin 7.3%.

Claims (10)

中藥配方菌群膠囊,其由糞菌分離後的凍乾粉和中藥萃取有效成分粉碎得到中藥萃取粉末配合製備得到;其中該糞菌分離後的凍乾粉的製備方法包括如下步驟:(1)用無菌採樣瓶收集健康供者的糞便樣本,密封送至無菌操作室,與無菌一次性使用耗材中的過濾瓶、AB瓶、除臭瓶、緩衝瓶和菌液瓶配合串聯放置在智能糞菌分離系統中進行菌群收集;(2)通過加液驅動裝置自動加注液體裝置將生理鹽水加注到採樣瓶中對糞便樣本進行浸泡;(3)打開氣泵將採樣瓶中的混合菌液依次通過不同過濾值的過濾網彙集到緩衝瓶中,再通過菌液驅動裝置將緩衝瓶中的菌液灌注到菌液瓶中後進行離心,離心完成去掉上清液,保留沉澱,此沉澱即為分離純化後的菌液沉澱;(4)向每個離心管中加入甘油,用振蕩器混勻,將其預凍,預凍完成後迅速將預凍後樣品進行冷凍乾燥,將凍乾後的菌液脫水後得到凍乾粉;該中藥萃取粉末是從由西洋參、黃精、神曲、地骨皮和莪術組成的中藥配方萃取的有效成分,進行粉碎得到。 The traditional Chinese medicine formula microflora capsule is prepared by cooperating with the freeze-dried powder after the separation of fecal bacteria and the extraction of the active ingredients of traditional Chinese medicine to obtain the traditional Chinese medicine extraction powder; wherein the preparation method of the freeze-dried powder after the separation of the fecal bacteria comprises the following steps: (1) Use sterile sampling bottles to collect fecal samples from healthy donors, seal them to the sterile operating room, and place them in series with the filter bottles, AB bottles, deodorizing bottles, buffer bottles and bacterial liquid bottles in sterile disposable consumables. Bacteria collection in the separation system; (2) Filling the normal saline into the sampling bottle to soak the fecal samples through the automatic liquid filling device through the liquid addition drive device; (3) Turning on the air pump to turn on the mixed bacterial liquid in the sampling bottle in turn Collected into the buffer bottle through filters with different filtration values, and then perfused the bacterial liquid in the buffer bottle into the bacterial liquid bottle through the bacterial liquid driving device, and then centrifuged. After centrifugation, the supernatant was removed and the precipitate was retained. The bacterial liquid precipitate after separation and purification; (4) Add glycerol to each centrifuge tube, mix with a shaker, and pre-freeze it. The lyophilized powder is obtained after the bacterial liquid is dehydrated; the traditional Chinese medicine extraction powder is obtained by pulverizing the active ingredients extracted from the traditional Chinese medicine formula composed of American ginseng, Polygonatum chinensis, Divine Comedy, Digupi and Curcuma Radix. 根據請求項1所述的中藥配方菌群膠囊,其中該採樣瓶中設有攪拌杆,步驟(2)中,採樣瓶中的攪拌杆對糞便樣品進行攪拌使其充分均質。 The traditional Chinese medicine formula flora capsule according to claim 1, wherein the sampling bottle is provided with a stirring rod, and in step (2), the stirring rod in the sampling bottle stirs the stool sample to make it fully homogenized. 根據請求項1或2所述的中藥配方菌群膠囊,其中該由糞菌分離後的凍乾粉和該中藥萃取粉末的體積比為0.5-2:1;其中該由糞菌分離後的
Figure 110120881-A0305-02-0020-14
凍乾粉和該中藥萃取粉末混勻是通過兩者混合後微型攪拌機攪拌混勻制得。
The traditional Chinese medicine formula flora capsule according to claim 1 or 2, wherein the volume ratio of the freeze-dried powder separated from the fecal bacteria and the Chinese medicine extraction powder is 0.5-2:1;
Figure 110120881-A0305-02-0020-14
The freeze-dried powder and the traditional Chinese medicine extraction powder are mixed uniformly by mixing the two and then agitating and mixing by a micro-mixer.
根據請求項3所述的中藥配方菌群膠囊,其中該由糞菌分離後的凍乾粉和所述的中藥萃取粉末的體積比為1:1。 The traditional Chinese medicine formula flora capsule according to claim 3, wherein the volume ratio of the freeze-dried powder separated from the fecal bacteria and the described traditional Chinese medicine extraction powder is 1:1. 根據請求項3所述的中藥配方菌群膠囊,其進一步地用耐酸羥丙甲纖維素膠囊灌裝得到中藥配方菌群膠囊。 The traditional Chinese medicine formula flora capsule according to claim 3 is further filled with acid-resistant hypromellose capsules to obtain the traditional Chinese medicine formula flora capsule. 根據請求項4所述的中藥配方菌群膠囊,其中:進一步地用耐酸羥丙甲纖維素膠囊灌裝得到中藥配方菌群膠囊。 The traditional Chinese medicine formula flora capsule according to claim 4, wherein: further fill with acid-resistant hypromellose capsules to obtain the traditional Chinese medicine formula flora capsule. 根據請求項1所述的中藥配方菌群膠囊,其中該中藥配方中西洋參、黃精、神曲、地骨皮、莪術的重量比為8-12:12-18:12-18:8-12:8-12。 The traditional Chinese medicine formula microflora capsule according to claim 1, wherein the weight ratio of American ginseng, Polygonatum chinensis, Divine Comedy, Digupi and Curcumae in the traditional Chinese medicine formula is 8-12:12-18:12-18:8-12: 8-12. 根據請求項7所述的中藥配方菌群膠囊,其中該中藥配方中西洋參、黃精、神曲、地骨皮、莪術的重量比為10:15:15:10:10。 The traditional Chinese medicine formula microflora capsule according to claim 7, wherein the weight ratio of American ginseng, Polygonatum chinensis, Divine Comedy, Digupi and Curcumae in the traditional Chinese medicine formula is 10:15:15:10:10. 根據請求項7或8所述的中藥配方菌群膠囊,其中該中藥萃取粉末製備方法如下,(1)按比例取藥材切碎或粉碎,置煎煮容器中;(2)加水浸泡;(3)加熱至沸,浸出,分離煎出液,藥渣依法煎出2-3次,收集煎出液;(4)將煎出液進行乙醇提取;(5)乙醇提取的濾液烘乾後再用超微粉碎機對其進行粉碎加工為低於10μm的超細粉。 The traditional Chinese medicine formula flora capsule according to claim 7 or 8, wherein the preparation method of the traditional Chinese medicine extraction powder is as follows: (1) chop or pulverize the medicinal materials in proportion, and place them in a decoction container; (2) add water to soak; (3) ) heating to boiling, leaching, separating the decocting liquid, the medicinal residues are decocted 2-3 times according to the law, and the decocting liquid is collected; (4) the decocting liquid is carried out ethanol extraction; (5) the filtrate of the ethanol extraction is dried and used again The ultrafine pulverizer pulverizes it into ultrafine powder below 10 μm . 一種如請求項1至9任一項所述的中藥配方菌群膠囊在製備治療2型糖尿病的藥物中的應用。 An application of the traditional Chinese medicine formula microflora capsule as described in any one of claims 1 to 9 in the preparation of a medicine for treating type 2 diabetes.
TW110120881A 2020-06-19 2021-06-09 Traditional chinese medicine formula flora capsule, preparation method and use thereof in preparing medicine for treating type 2 diabetes TWI777606B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010567022.1 2020-06-19
CN202010567022.1A CN111544550B (en) 2020-06-19 2020-06-19 Traditional Chinese medicine formula flora capsule, preparation method and application in preparation of medicine for treating type 2 diabetes

Publications (2)

Publication Number Publication Date
TW202135848A TW202135848A (en) 2021-10-01
TWI777606B true TWI777606B (en) 2022-09-11

Family

ID=72007064

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110120881A TWI777606B (en) 2020-06-19 2021-06-09 Traditional chinese medicine formula flora capsule, preparation method and use thereof in preparing medicine for treating type 2 diabetes

Country Status (3)

Country Link
JP (1) JP2022001572A (en)
CN (1) CN111544550B (en)
TW (1) TWI777606B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114350520A (en) * 2022-01-19 2022-04-15 厦门承葛生物科技有限公司 Method for filtering and extracting intestinal flora
CN115969034B (en) * 2022-11-01 2023-12-22 嫦娥创新(武汉)生物科技有限公司 Oral freeze-dried powder for diabetics and preparation method thereof
CN115887604A (en) * 2023-01-06 2023-04-04 杭州络通生物科技有限公司 Research on drug for treating type II diabetes by using citrus reticulata blanco and liquorice extracts

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105624024A (en) * 2014-10-31 2016-06-01 南京法迈特科技发展有限公司 Separation device of microorganisms in gastrointestinal tract contents
CN110638782A (en) * 2019-09-16 2020-01-03 广东南芯医疗科技有限公司 Method for preparing capsule

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100956278B1 (en) * 2009-08-03 2010-05-10 대한약품공업 주식회사 Composition comprising an extract of herbal combination thereof for preventing and treating diabetes mellitus
RU2013109251A (en) * 2010-08-04 2014-09-10 Томас Джулиус БОРОДИ COMPOSITIONS FOR TRANSPLANTATION OF FEKAL FLORA AND METHODS FOR THEIR RECEIVING AND APPLICATION AND DEVICES FOR THEIR DELIVERY
KR20150103012A (en) * 2012-11-26 2015-09-09 토마스 줄리어스 보로디 Compositions for the restoration of a fecal microbiota and methods for making and using them
CN104922158B (en) * 2015-06-05 2018-11-02 中国人民解放军第三军医大学第三附属医院 Caprophyl capsule and its preparation and application
CN105749064A (en) * 2016-05-09 2016-07-13 林荣波 Traditional Chinese medicine composition with blood glucose reduction function
CN106492117A (en) * 2016-11-30 2017-03-15 王江波 A kind of Chinese medicine composition for treating diabetes
CN110404044A (en) * 2019-09-05 2019-11-05 孙成栋 A kind of hypoglycemic drug and preparation method thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105624024A (en) * 2014-10-31 2016-06-01 南京法迈特科技发展有限公司 Separation device of microorganisms in gastrointestinal tract contents
CN110638782A (en) * 2019-09-16 2020-01-03 广东南芯医疗科技有限公司 Method for preparing capsule

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
網路文獻 魏耕樹, 益氣活血湯治療2型糖尿病胰島素抵抗38例, 現代中醫藥, 2010年5月 第30卷第3期; *
網路文獻 黃小靖 等, 地骨皮治療糖尿病的研究進展, 光明中醫, 2018年11月 第33卷第22期 *

Also Published As

Publication number Publication date
TW202135848A (en) 2021-10-01
CN111544550B (en) 2021-11-09
CN111544550A (en) 2020-08-18
JP2022001572A (en) 2022-01-06

Similar Documents

Publication Publication Date Title
TWI777606B (en) Traditional chinese medicine formula flora capsule, preparation method and use thereof in preparing medicine for treating type 2 diabetes
CN106074971A (en) A kind of hypoglycemic traditional Chinese medicine composition and preparation method and application
CN107997176A (en) A kind of stomach strengthening and digestion promoting health food for preventing children&#39;s having indigestion apocleisis
JP2005021006A (en) Food and drink material, food and drink, and antidote each shortly eliminating alcohol-induced influence
CN111195314A (en) Traditional Chinese medicine composition for nourishing stomach and promoting digestion and preparation method thereof
JP2011522844A (en) Composition for reducing blood glucose level and use thereof
CN1403138A (en) Compound Chinese medicine prepn for treating urinary system infection and prostatitis and its prepn process
CN106361842A (en) Anti-fatigue healthcare capsules
CN103920140A (en) Compound preparation for reducing blood glucose, body weight and fat for human
JP2021518852A (en) Chinese herbal medicine composition for treating cardiovascular disease or cerebrovascular disease, its preparation method and use
CN101693084B (en) Medical composition for treating epigastric pain yin deficiency syndrome and preparation method thereof
CN113813331A (en) Composition with throat clearing function and preparation method and application thereof
CN104887766A (en) Traditional Chinese medicine compound capsules for treating atherosclerosis and preparation method thereof
CN116159102B (en) Traditional Chinese medicine composition for treating postprandial discomfort syndrome as well as preparation method and application thereof
CN101966251B (en) Medicinal composition for preventing and treating bronchial asthma and preparation and application thereof
CN116370548B (en) Traditional Chinese medicine composition with effect of improving polycystic ovarian syndrome and preparation method and application thereof
CN115779046B (en) Traditional Chinese medicine composition, traditional Chinese medicine preparation and application for preventing and treating diabetes
CN104491637B (en) It is a kind of to treat compound composite medicament of cough after common cold and preparation method and application
CN1261156C (en) Medicine for treating chronic gastroenteritis and colitis
CN109925469A (en) A kind of Chinese medicine composition that treating liver-depression and spleen-insufficiency type nonalcoholic fatty liver and application
CN106540006A (en) With Immune-enhancing effect, the composition of anti-inflammatory antiviral activity and preparation method thereof
CN105250919B (en) It is a kind of for preventing and/or the Chinese medicine composition for treating liver disease and preparation method thereof
CN105853879A (en) Traditional Chinese medicine for treating ulcerative colitis
CN1189191C (en) Nephrosis treating medicine and its prepn
CN104825980A (en) Traditional Chinese medicine preparation for treating diarrhea

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent